Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRueda-Martínez, Carmen
dc.contributor.authorLamas, Oscar
dc.contributor.authorMataró, María José
dc.contributor.authorRobledo-Carmona, Juan
dc.contributor.authorSánchez-Espín, Gemma
dc.contributor.authorMoreno-Santos, Inmaculada
dc.contributor.authorCarrasco-Chinchilla, Fernando
dc.contributor.authorGallego, Pastora
dc.contributor.authorSuch-Martínez, Miguel
dc.contributor.authorde Teresa, Eduardo
dc.contributor.authorJiménez-Navarro, Manuel
dc.contributor.authorFernández, Borja
dc.description.abstractBicuspid aortic valve (BAV) is the most prevalent congenital cardiac malformation, frequently associated with aortic dilatation (AD). The molecular mechanisms involved in AD and its aetiological link with BAV formation are poorly understood. Altered fibrillin-1 (FBN1) and metalloprotease-2, -9 (MMP2,9) protein activities have been suggested to be involved in BAV aortopathy. In addition, FBN2 participates in embryonic valve formation, but its possible involvement in BAV-associated AD has never been explored. In this report, we evaluate the expression levels of MMP2,9 and FBN1,2 in the ascending aorta of patients with normal or dilated aortas and with tricuspid aortic valve (TAV) or BAV, using appropriate tissue-specific reference genes. Gene expression was quantified by real-time quantitative polymerase chain reaction in 52 patients, using one or three reference genes previously validated in the same patient population. FBN2 expression was significantly increased in the aortas of patients with BAV compared with individuals with TAV (0.178 ± 0.042 vs 0.096 ± 0.021, P = 0.015), whereas differences in FBN1 did not reach statistical significance (1.946 ± 0.228 vs 1.430 ± 0.114, P = 0.090). When four groups of samples were considered, FBN2 expression was significantly higher in patients with BAV and AD compared with patients with TAV and AD (0.164 ± 0.035 vs 0.074 ± 0.027, P = 0.040). No significant differences were found when FBN1/FBN2 ratio, and MMP2 and MMP9 expression levels were analysed. No linear relationship between aortic diameter and gene expression levels were found. BAV patients have an increased FBN (especially FBN2) gene expression level in the ascending aorta, irrespective of dilatation, whereas MMP expression does not change significantly. These results add a new piece of information to the pathophysiology of BAV disease and point to FBN2 as a new molecular player.
dc.subjectAortic aneurysm
dc.subjectBicuspid aortic valve
dc.subject.meshAorta, Thoracic
dc.subject.meshAortic Valve
dc.subject.meshBicuspid Aortic Valve Disease
dc.subject.meshGene Expression Regulation
dc.subject.meshHeart Valve Diseases
dc.subject.meshMiddle Aged
dc.subject.meshReal-Time Polymerase Chain Reaction
dc.titleFibrillin 2 is upregulated in the ascending aorta of patients with bicuspid aortic valve.
dc.typeresearch article
dc.rights.accessRightsopen access
dc.journal.titleEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
dc.journal.titleabbreviationEur J Cardiothorac Surg
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.organizationHospital Universitario Virgen de la Victoria
dc.organizationHospital Universitario Virgen Macarena
dc.pubmedtypeJournal Article
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.